Latest news and upcoming events
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve
Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions
Adcendo Appoints Michael Pehl as Chief Executive Officer
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program.
Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ
This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.
AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of sepsis-associated acute kidney injury (SA-AKI).
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board
The new SAB will be comprised of seven members and will work closely with Aura’s senior management.
AM-Pharma Appoints Martijn Negen as VP Commercial Strategy
Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board
VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting
These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.